GO:0045861 negative regulation of proteolysis: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045861 (negative regulation of proteolysis) describes any process that stops, prevents, or reduces the hydrolysis of peptide bonds within proteins, as defined by QuickGO.
• This term covers diverse molecular strategies, including ubiquitin-mediated degradation of proteases, competitive inhibition, and proteolytic cleavage events that inactivate rather than activate substrates [1, 4, 7].
• Key regulators include E3 ubiquitin ligases such as KLHL6, DTX3L, and RNF90, which target proteins for proteasomal degradation and thereby indirectly control proteolysis [1, 6, 8].
• Dysregulation of negative regulation of proteolysis contributes to cancer progression, immune evasion, and impaired DNA repair, making it a therapeutic target [2, 6, 8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of these regulatory pathways in disease-relevant cell types [1, 2, 8].
• Studying this process requires integrated approaches such as proteomics, ubiquitin enrichment, and functional assays to distinguish direct from indirect effects [3, 4, 5].
Description
Negative regulation of proteolysis (GO:0045861) is a biological process that reduces the frequency, rate, or extent of peptide bond hydrolysis within proteins. Proteolysis is essential for protein turnover, signaling, and quality control, but unrestrained activity can be deleterious; thus, cells deploy multiple layers of negative regulation to maintain proteostasis [4, 5]. This term encompasses mechanisms such as ubiquitination and degradation of proteases, inhibitory protein-protein interactions, and cleavage events that render a protease inactive [1, 7]. Understanding GO:0045861 is critical because its disruption is linked to cancer, immune disorders, and neurodegenerative conditions [2, 6, 8]. Researchers studying this process often focus on E3 ligases, deubiquitinases, and protease inhibitors that modulate proteolytic cascades [1, 4, 6].
negative regulation of proteolysis At A Glance
| GO ID | GO:0045861 |
|---|---|
| GO term | negative regulation of proteolysis |
| Ontology | biological_process |
| Synonym | down regulation of proteolysis, down-regulation of proteolysis, downregulation of proteolysis, inhibition of proteolysis, negative regulation of peptidolysis |
| Major function | Reduces the hydrolysis of peptide bonds within proteins, thereby controlling protein stability and signaling. |
| Regulatory mechanisms | Ubiquitin-proteasome degradation of proteases, inhibitory binding, and inactivating cleavage [1, 4, 7]. |
| Key regulators | E3 ubiquitin ligases (e.g., KLHL6, DTX3L, RNF90), deubiquitinases, and protease inhibitors [1, 6, 8]. |
| Disease relevance | Cancer, immune dysregulation, and DNA repair defects [2, 6, 8]. |
What Is GO:0045861?
According to QuickGO, negative regulation of proteolysis (GO:0045861) is any process that stops, prevents, or reduces the frequency, rate, or extent of the hydrolysis of a peptide bond or bonds within a protein. It is a biological process that acts as a brake on proteolytic enzymes, ensuring that protein degradation occurs only when and where needed. This regulation can be achieved by degrading the protease itself, by binding inhibitors, or by post-translational modifications that inactivate the protease [1, 4, 7].
Why Is negative regulation of proteolysis Important in Cell Biology?
Negative regulation of proteolysis is fundamental to cellular homeostasis because it prevents excessive protein degradation that could otherwise destroy essential signaling molecules or structural proteins. It also fine-tunes immune responses, as seen in the regulation of TLR9 and MAVS by proteolytic events [6, 7]. In cancer, loss of negative regulation can lead to unchecked protease activity that promotes invasion and metastasis. Thus, understanding GO:0045861 provides insights into basic cell biology and identifies targets for therapeutic intervention [1, 8].
• Maintains proteostasis by preventing runaway proteolysis.
• Controls immune signaling through regulated cleavage of receptors and adaptors [6, 7].
• Modulates DNA repair pathway choice via degradation of repair factors.
• Influences cancer progression by regulating focal adhesion kinase stability.
• Affects neuronal autophagy by controlling degradation of negative regulators.
• Regulates bacterial envelope stress responses.
• Provides targets for cancer therapy, e.g., PARP inhibitor sensitivity.
• Impacts T cell function and resistance to dysfunction.
• Offers biomarkers for triple-negative breast cancer.
• Enables development of CRISPR models to dissect regulatory networks [1, 4, 8].
What Happens During negative regulation of proteolysis?
Ubiquitin-mediated degradation of proteases
In simple terms: Cells tag proteases with ubiquitin so they get destroyed, reducing proteolysis.
E3 ubiquitin ligases such as KLHL6 and DTX3L attach ubiquitin chains to target proteins, leading to their proteasomal degradation [1, 8]. For example, KLHL6 drives resistance to CD8+ T cell dysfunction by targeting a negative regulator for degradation. Similarly, DTX3L mediates TIRR nuclear export and degradation, influencing DNA repair. This mechanism indirectly reduces proteolysis by eliminating the proteases themselves.
Inhibitory cleavage events
In simple terms: Sometimes a protease cuts a protein in a way that turns off its function instead of activating it.
Proteolytic cleavage can inactivate a protein, as seen in the complex negative regulation of TLR9 by multiple cleavage events. These cleavages prevent downstream signaling, effectively reducing proteolysis of other substrates. This illustrates how proteolysis itself can be a mechanism of negative regulation.
Competitive inhibition and sequestration
In simple terms: Inhibitor proteins bind to proteases and block their active sites.
Although specific examples are limited in the provided citations, general protease inhibitors can sequester proteases. In the bacterial envelope, regulation of proteolysis involves such mechanisms to maintain homeostasis. This subsection highlights that negative regulation can occur at the level of enzyme availability.
Regulation of autophagy-related proteolysis
In simple terms: Autophagy is a form of protein degradation, and its negative regulation prevents excessive breakdown.
UBA6-BIRC6-mediated ubiquitination of LC3 negatively regulates autophagy, thereby reducing autophagic proteolysis. Mitochondrial damage triggers concerted degradation of negative regulators of neuronal autophagy, which would otherwise suppress autophagy. These examples show that negative regulation of proteolysis intersects with autophagy pathways.
Key Genes Involved in GO:0045861 negative regulation of proteolysis
The following genes and proteins are experimentally implicated in negative regulation of proteolysis, based on the verified citations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLHL6 | E3 ubiquitin ligase that targets proteins for degradation, influencing T cell function | Studied in CD8+ T cell dysfunction and resistance |
| DTX3L | E3 ubiquitin ligase mediating TIRR degradation and nuclear export | Linked to DNA repair and PARP inhibitor sensitivity |
| RNF90 | E3 ubiquitin ligase that negatively regulates MAVS-mediated antiviral signaling | Role in RNA virus-triggered immune responses |
| UBA6 | Ubiquitin-activating enzyme involved in LC3 ubiquitination | Regulates autophagy and proteolysis |
| BIRC6 | E3 ubiquitin ligase that partners with UBA6 to ubiquitinate LC3 | Negative regulation of autophagy |
| FAK | Focal adhesion kinase; its proteolysis is inhibited by FAISL | Triple-negative breast cancer progression |
| Calpain 2 | Protease that cleaves FAK; inhibited by lncRNA FAISL | Cancer metastasis |
| TLR9 | Toll-like receptor 9; negatively regulated by proteolytic cleavage | Immune signaling |
| MAVS | Mitochondrial antiviral signaling protein; targeted by RNF90 | Antiviral immunity |
| LC3 | Autophagy marker; ubiquitination by UBA6-BIRC6 inhibits autophagy | Autophagy regulation |
| TIRR | Protein involved in DNA repair; degraded by DTX3L | DNA repair pathway choice |
| FAISL | LncRNA that inhibits calpain 2-mediated proteolysis of FAK | Breast cancer metastasis |
| KLHL6 substrate | Unknown substrate in T cells | T cell dysfunction |
| BIRC6 | Inhibitor of apoptosis and regulator of autophagy | Cell survival and autophagy |
| Calpain | Calcium-dependent protease | Cancer and neurodegeneration |
| Proteasome | Multi-subunit protease complex [1, 8] | Protein degradation [1, 8] |
| Autophagy machinery | Includes LC3 and related proteins [3, 4] | Neuronal autophagy [3, 4] |
How Is negative regulation of proteolysis Regulated?
Negative regulation of proteolysis is itself regulated at multiple levels. For instance, the ubiquitin-proteasome system controls the stability of proteases and their regulators [1, 8]. In neuronal autophagy, mitochondrial damage triggers the degradation of negative regulators, thereby activating autophagy. Additionally, lncRNA FAISL inhibits calpain 2-mediated proteolysis of FAK, illustrating RNA-level control. These examples show that negative regulation is dynamically modulated by cellular stress, immune signals, and non-coding RNAs.
negative regulation of proteolysis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FAISL | Triple-negative breast cancer metastasis | Knockout of FAISL in TNBC cell lines to assess FAK stability and invasion |
| DTX3L | DNA repair defects and PARP inhibitor sensitivity | Knockout or point mutation in cancer cells followed by PARP inhibitor treatment |
| RNF90 | Antiviral immune dysregulation | Knockout in macrophages or fibroblasts to measure MAVS degradation and viral replication |
| KLHL6 | T cell dysfunction | Knockout in CD8+ T cells to study resistance to dysfunction |
| UBA6/BIRC6 | Autophagy-related disorders | Knockout or overexpression in neuronal cells to monitor LC3 ubiquitination |
Cancer
In triple-negative breast cancer, lncRNA FAISL inhibits calpain 2-mediated proteolysis of FAK, promoting progression and metastasis. Loss of negative regulation can lead to increased FAK stability and invasive behavior. Similarly, DTX3L-mediated degradation of TIRR affects DNA repair and PARP inhibitor sensitivity, highlighting therapeutic opportunities.
Immune disorders
RNF90 negatively regulates RNA virus-triggered antiviral immune responses by targeting MAVS. Dysregulation of this process can lead to impaired antiviral defense or autoimmunity. TLR9 is also subject to complex negative regulation by proteolytic cleavage, affecting immune signaling.
Neurodegeneration
Mitochondrial damage triggers the concerted degradation of negative regulators of neuronal autophagy, linking negative regulation of proteolysis to neuronal survival. Defects in this pathway may contribute to neurodegenerative diseases characterized by impaired autophagy.
From negative regulation of proteolysis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KLHL6 affect T cell dysfunction? | KLHL6 knockout in primary CD8+ T cells or cell lines |
| Does FAISL inhibit calpain 2-mediated FAK proteolysis? | FAISL knockout or overexpression in TNBC cells |
| Does DTX3L-mediated TIRR degradation influence PARP inhibitor sensitivity? | DTX3L knockout or point mutation in cancer cells |
| Does RNF90 regulate MAVS stability? | RNF90 knockout or overexpression in immune cells |
| Does UBA6-BIRC6 ubiquitination of LC3 affect autophagy? | UBA6 or BIRC6 knockout in neuronal cells |
| Does mitochondrial damage trigger degradation of autophagy negative regulators? | Knock-in of tagged regulators or knockout of specific E3 ligases |
How to Study the negative regulation of proteolysis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Protein levels and cleavage products | Assessing FAK proteolysis |
| Immunoprecipitation | Protein-protein interactions and ubiquitination | Detecting LC3 ubiquitination |
| Mass spectrometry | Global protein degradation and ubiquitin chains | Identifying substrates of KLHL6 |
| Protease activity assay | Enzymatic activity of proteases | Measuring calpain 2 activity |
| CRISPR knockout screen | Genes affecting a phenotype | Finding regulators of MAVS |
| Live-cell imaging | Autophagy flux and protein localization | Tracking mitochondrial damage-induced degradation |
| RNA-seq | Transcriptional changes | Measuring immune response genes |
| Flow cytometry | Cell surface markers and viability | Assessing T cell dysfunction |
Proteomics and ubiquitin enrichment
Mass spectrometry-based proteomics can identify proteins that are degraded upon activation of negative regulation pathways. Ubiquitin enrichment followed by proteomics reveals substrates of E3 ligases such as KLHL6 and DTX3L [1, 8].
Functional assays for proteolysis
Protease activity assays and cleavage-specific antibodies can measure the rate of proteolysis. For example, FAK cleavage by calpain 2 can be monitored by western blot. TLR9 cleavage events can be assessed by immunoprecipitation.
Autophagy flux analysis
LC3 lipidation and turnover are standard readouts for autophagy. UBA6-BIRC6-mediated ubiquitination of LC3 can be studied by immunoprecipitation and western blot. Mitochondrial damage-induced degradation of autophagy regulators can be tracked by live imaging.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that regulate proteolysis. For instance, screens in immune cells can uncover regulators of MAVS stability. Libraries targeting E3 ligases are particularly useful [1, 8].
How CRISPR Can Be Used to Study GO:0045861 negative regulation of proteolysis
Knockout
CRISPR knockout of genes such as KLHL6, DTX3L, or RNF90 can reveal their role in negative regulation of proteolysis. For example, KLHL6 knockout in CD8+ T cells may increase dysfunction. DTX3L knockout can sensitize cells to PARP inhibitors.
Point Mutation
Introducing point mutations in catalytic residues of E3 ligases or protease active sites can dissect enzymatic vs. scaffolding functions. For instance, mutating the RING domain of RNF90 would test its ligase activity in MAVS regulation.
Knock-in
Knock-in of tagged versions (e.g., HA- or GFP-tagged) of LC3 or FAK allows tracking of proteolysis in live cells [2, 4]. Tagged knock-in of TIRR can monitor DTX3L-mediated degradation.
Overexpression
Overexpression of lncRNA FAISL or protease inhibitors can suppress proteolysis and assess downstream effects. Overexpression of UBA6 and BIRC6 can enhance LC3 ubiquitination and inhibit autophagy.
How EDITGENE Supports negative regulation of proteolysis Research
Researchers studying negative regulation of proteolysis-related genes often need to determine whether a candidate gene is causally involved in controlling proteolytic events or is merely a bystander. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides end-to-end CRISPR services to accelerate such discoveries.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of proteolysis research.
Frequently Asked Questions About negative regulation of proteolysis
What is negative regulation of proteolysis GO:0045861?
It is a biological process that stops, prevents, or reduces the hydrolysis of peptide bonds within proteins, as defined by QuickGO.
What genes are involved in negative regulation of proteolysis?
Key genes include KLHL6, DTX3L, RNF90, UBA6, BIRC6, and FAISL, among others [1, 2, 4, 6, 8].
How does ubiquitination regulate proteolysis?
E3 ubiquitin ligases tag proteases or their regulators for proteasomal degradation, thereby reducing proteolytic activity [1, 8].
What diseases are linked to negative regulation of proteolysis?
Cancer, immune disorders, and neurodegeneration are associated with dysregulation of this process [2, 3, 6, 8].
What is the role of KLHL6 in T cell dysfunction?
KLHL6 is an E3 ligase that drives resistance to CD8+ T cell dysfunction by targeting a negative regulator for degradation.
How does FAISL inhibit calpain 2-mediated proteolysis?
FAISL is a lncRNA that inhibits calpain 2-mediated cleavage of FAK, promoting cancer progression.
What experimental models are used to study negative regulation of proteolysis?
CRISPR knockout, point mutation, knock-in, and overexpression models in cell lines and primary cells are commonly used [1, 2, 4, 8].
What methods measure proteolysis rates?
Western blot, protease activity assays, mass spectrometry, and live-cell imaging are standard methods [2, 3, 4].
How does DTX3L affect DNA repair?
DTX3L mediates TIRR degradation, influencing DNA repair pathway choice and PARP inhibitor sensitivity.
Can CRISPR screens identify regulators of proteolysis?
Yes, genome-wide CRISPR screens can uncover genes that modulate proteolysis, such as RNF90 in antiviral immunity.
Conclusion
Negative regulation of proteolysis (GO:0045861) is a vital biological process that safeguards cells from excessive protein degradation. Its mechanisms range from ubiquitin-mediated degradation of proteases to inhibitory cleavage events, and its dysregulation underpins cancer, immune disorders, and neurodegeneration [1, 2, 6, 8]. By leveraging CRISPR models and multi-omics approaches, researchers can dissect these pathways and identify new therapeutic targets. EDITGENE offers comprehensive services to support such studies, from knockout to library screening.
References
- 1. Cheng H et al.. 2026. The ubiquitin ligase KLHL6 drives resistance to CD8(+) T cell dysfunction.. Nature 651(8105):451-461 PMID: 41535474
- 2. Zhang Y et al.. 2024. LncRNA FAISL Inhibits Calpain 2-Mediated Proteolysis of FAK to Promote Progression and Metastasis of Triple Negative Breast Cancer.. Adv Sci (Weinh) 11(42):e2407493 PMID: 39287113
- 3. Basak B et al.. 2025. Mitochondrial damage triggers the concerted degradation of negative regulators of neuronal autophagy.. Nat Commun 16(1):7367 PMID: 40783388
- 4. Jia R et al.. 2019. Negative regulation of autophagy by UBA6-BIRC6-mediated ubiquitination of LC3.. Elife 8 PMID: 31692446
- 5. Raivio TL. 2018. Regulation of Proteolysis in the Gram-Negative Bacterial Envelope.. J Bacteriol 200(3) PMID: 29109189
- 6. Yang B et al.. 2021. Negative Regulation of RNF90 on RNA Virus-Triggered Antiviral Immune Responses Targeting MAVS.. Front Immunol 12:730483 PMID: 34512666
- 7. Sinha SS et al.. 2016. Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events.. J Immunol 197(4):1343-52 PMID: 27421483
- 8. Ye Q et al.. 2024. DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity.. Nat Commun 15(1):10596 PMID: 39632881
